Assertio Holdings NASDAQASRT investor five-year losses grow to 72 percent as the stock sheds US17m this past week
| ASRT Stock | USD 0.68 0.01 1.45% |
Slightly above 56% of all Assertio Therapeutics' private investors are looking to take a long position. The analysis of overall sentiment of trading Assertio Therapeutics stock suggests that some investors are interested at this time. Assertio Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Assertio Therapeutics' earnings reports, geopolitical events, and overall market trends.
Long term investing works well, but it doesnt always work for each individual stock. We dont wish catastrophic...
Read at simplywall.st
 |
Assertio Therapeutics Fundamental Analysis
We analyze Assertio Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Assertio Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Assertio Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Valuation
Current Valuation Comparative Analysis
Assertio Therapeutics is currently under evaluation in current valuation category among its peers. Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Assertio Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Assertio Therapeutics stock to make a market-neutral strategy. Peer analysis of Assertio Therapeutics could also be used in its relative valuation, which is a method of valuing Assertio Therapeutics by comparing valuation metrics with similar companies.
Peers
Assertio Therapeutics Related Equities
| IRWD | Ironwood Pharmaceuticals | 6.78 | ||||
| ESPR | Esperion Therapeutics | 4.82 | ||||
| AMPH | Amphastar | 1.50 | ||||
| PCRX | Pacira BioSciences, | 1.45 | ||||
| RDY | Dr Reddys | 1.30 | ||||
| AMRX | Amneal Pharmaceuticals, | 1.25 | ||||
| ALKS | Alkermes Plc | 1.17 | ||||
| COLL | Collegium Pharmaceutical | 0.93 | ||||
| ANIP | ANI Pharmaceuticals | 0.78 | ||||
| NBIX | Neurocrine Biosciences | 0.51 | ||||
| LFCR | Lifecore Biomedical | 0.72 | ||||
| ALVO | Alvotech | 1.32 | ||||
| EOLS | Evolus | 5.20 |
Additional Tools for Assertio Stock Analysis
When running Assertio Therapeutics' price analysis, check to measure Assertio Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Assertio Therapeutics is operating at the current time. Most of Assertio Therapeutics' value examination focuses on studying past and present price action to predict the probability of Assertio Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Assertio Therapeutics' price. Additionally, you may evaluate how the addition of Assertio Therapeutics to your portfolios can decrease your overall portfolio volatility.